MENU
+Compare
JANX
Stock ticker: NASDAQ
AS OF
Apr 3, 04:59 PM (EDT)
Price
$27.06
Change
-$1.19 (-4.21%)
Capitalization
1.67B

JANX Janux Therapeutics Forecast, Technical & Fundamental Analysis

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer... Show more

JANX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for JANX with price predictions
Apr 02, 2025

JANX's RSI Indicator ascending out of oversold territory

The RSI Indicator for JANX moved out of oversold territory on April 02, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 23 similar instances when the indicator left oversold territory. In of the 23 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Moving Average Convergence Divergence (MACD) for JANX just turned positive on April 02, 2025. Looking at past instances where JANX's MACD turned positive, the stock continued to rise in of 33 cases over the following month. The odds of a continued upward trend are .

JANX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on March 26, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on JANX as a result. In of 65 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where JANX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for JANX entered a downward trend on April 02, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.633) is normal, around the industry mean (13.260). P/E Ratio (0.000) is within average values for comparable stocks, (64.931). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.878). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (142.857) is also within normal values, averaging (252.036).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. JANX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. JANX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
JANX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

JANX is expected to report earnings to rise 2.03% to -36 cents per share on May 13

Janux Therapeutics JANX Stock Earnings Reports
Q1'25
Est.
$-0.37
Q4'24
Beat
by $0.07
Q3'24
Missed
by $0.18
Q2'24
Beat
by $0.20
Q1'24
Beat
by $0.04
The last earnings report on February 27 showed earnings per share of -36 cents, beating the estimate of -42 cents. With 390.46K shares outstanding, the current market capitalization sits at 1.67B.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
10955 Vista Sorrento Parkway
Phone
+1 858 751-4493
Employees
64
Web
https://www.januxrx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HCAIX94.260.80
+0.86%
Harbor Capital Appreciation Inv
NAPIX61.37N/A
N/A
Voya Multi-Manager International Sm Cp I
HGHSX38.58N/A
N/A
Hartford Healthcare R4
PWDAX9.52N/A
N/A
Donoghue Forlines Dividend A
PNSCX53.03N/A
N/A
Putnam Small Cap Growth C

JANX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, JANX has been loosely correlated with DNLI. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if JANX jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To JANX
1D Price
Change %
JANX100%
+5.37%
DNLI - JANX
46%
Loosely correlated
+11.80%
SKYE - JANX
41%
Loosely correlated
+2.14%
LGND - JANX
39%
Loosely correlated
+3.73%
OCUL - JANX
37%
Loosely correlated
+12.23%
NUVB - JANX
36%
Loosely correlated
+2.29%
More